The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 356:2544-2546 June 14, 2007 Number 24
NextNext

The Failing Heart

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Neubauer, S.
-PubMed Citation
To the Editor: The review article by Neubauer (March 15 issue),1 which focuses on myocardial energetics, states that the use of fatty acids and glucose is decreased and insulin resistance develops in advanced heart failure. Neubauer also suggests some new drug targets for the treatment of heart failure in the peroxisome proliferator–activated receptor (PPAR) family, including PPAR{alpha} and PPAR{gamma} coactivator 1. We want to add PPAR{delta} to the list. PPAR{delta} is another isotype of the PPAR family.2 Cheng et al.3 discovered that a heart that is deficient in PPAR{delta} has decreased fatty acid oxidation and lipotoxic cardiomyopathy, and Planavila et . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.